首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1881346

全球蛋白質療法市場（依產品、應用和地區劃分）－市場規模、產業趨勢、機會分析及預測（2025-2033 年）

Global Protein Therapeutics Market: By Product, Applications, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2025-2033

出版日期: 2025年11月11日 | 出版商:

Astute Analytica | 英文 280 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

目前，該市場正經歷強勁且充滿活力的成長，預計到 2024 年市場規模將達到 2,298 億美元。這一成長趨勢預計將在未來幾年持續強勁，預計到 2033 年，市場規模將成長近一倍，達到 4,268 億美元。這一成長意味著 2025 年至 2033 年預測期內的複合年增長率 (CAGR) 為 7.12%，反映了各個治療領域持續且加速成長的需求。

推動這令人矚目的成長因素有很多。其中一個關鍵推動因素是神經病學領域一系列突破性監管審批的出台，這些審批促成了針對複雜神經系統疾病的創新生物療法的問世。這些新療法滿足了以往未被滿足的醫療需求，並為患有慢性且往往致殘性疾病的患者帶來了希望。同時，GLP-1受體激動劑的處方量顯著增長，尤其是在糖尿病和肥胖等代謝性疾病的治療方面。

市場趨勢

蛋白質療法市場的競爭策略圍繞著精準標靶療法（例如單株抗體 (mAb)）的開發、研發方面的大量投資以及獲得監管支持以加快新生物製劑的審批。各公司越來越關注精準醫療方法，以實現針對特定疾病機制的個人化治療，而單株抗體由於其靶向分子通路的能力，正是這一趨勢的體現。

這一趨勢的一個顯著例子是，AbraBio與武田藥品工業株式會社於2025年10月達成一項多年研究合作，旨在利用人工智慧推進蛋白質療法的設計。此次合作標誌著人工智慧和生物技術的融合日益加深，各公司正利用運算工具加速新型蛋白質藥物的發現和優化。作為協議的一部分，Avrabio 將獲得一筆預付款和持續的研究經費，並有可能獲得超過 10 億美元的成功付款，這凸顯了尖端蛋白質療法開發的高風險和財務投入。

為了進一步說明該領域蓬勃發展的融資環境，2025 年 6 月，專注於體內蛋白質療法生產的先鋒生物技術公司 Signify Bio 宣布完成了超額認購的 1500 萬美元首輪融資。本輪融資由 Actium Group 領投，其他知名投資者包括蓋茲基金會戰略投資基金、丹納赫創投公司（丹納赫集團子公司）、禮來公司以及美國癌症協會 (ACS) 的創投機構 BrightEdge。

核心成長驅動因子

細胞和基因療法 (CGT) 的快速發展正在更廣泛的蛋白質療法市場中創造對高度專業化蛋白質的巨大新需求。這些先進療法高度依賴蛋白質成分，特別是作為將遺傳物質遞送到患者細胞的載體。到 2024 年初，已有超過 420 種利用蛋白質載體的基因療法進入臨床試驗階段，這表明蛋白質在這些創新療法的開發和功能中發揮著至關重要的作用。

新興機會

血漿蛋白療法市場預計將迎來顯著成長，主要受兩大因素驅動：原材料供應鏈的不斷擴大以及對先進療法日益增長的臨床需求。推動這一成長的關鍵因素是血漿採集網路的快速擴張，這對於滿足全球患者不斷增長的治療需求至關重要。光是在美國，CSL Plasma 和 Octapharma 等大型血漿採集公司就大幅擴展業務。例如，CSL Plasma 已將其採集中心擴展到 300 多個地點，反映出增加血漿供應對於支持血漿衍生藥物生產的重要性。

優化障礙

蛋白質療法的開發和生產成本高昂，是可能阻礙市場成長的一大障礙。開發這些先進的生物製劑是一個複雜的過程，涉及廣泛的研究、臨床試驗和嚴格的監管要求，所有這些都需要大量的資金投入。生產階段也增加了額外的成本，因為生產蛋白質類藥物需要專門的設施、先進的技術和嚴格的品質控制措施，以確保安全性和有效性。這些成本的累積效應會導致最終產品價格高昂，從而限制患者的獲得。

產業價值鏈分析
- 原料供應商
- 製造商
- 經銷商
- 製程類型
行業展望
PESTLE 分析
波特五力分析
- 供應商議價能力
- 買方議價能力
- 替代品威脅
- 新進入者威脅
- 競爭強度
市場動態與趨勢
- 成長推動因素
- 阻礙因素
- 挑戰
- 主要趨勢
市場成長與展望
- 市場收入估計與預測（2020-2033）
- 價格趨勢分析
競爭格局概覽
- 市場集中度
- 公司競爭佔有率分析（價值，2024 年）
- 競爭格局分析與基準分析
實務洞察（分析師建議）

第五章全球蛋白質療法市場分析：依產品分類

主要洞察
市場規模及預測（2020-2033 年）
- 單株抗體
- 胰島素
- 融合蛋白
- 促紅血球生成素
- 幹擾素
- 人類生長激素
- 促卵泡激素

第六章：全球蛋白質療法市場分析：依應用領域劃分

主要見解
市場規模及預測（2020-2033）
- 代謝性疾病
- 免疫系統疾病
- 血液系統疾病
- 癌症
- 內分泌疾病
- 遺傳性疾病

第七章：全球蛋白質療法市場區域分析

主要見解
市場規模及預測（2020-2033）
- 北美
- 歐洲
- 亞太地區
- 中東和非洲
- 南美

第八章：北美蛋白質療法市場分析

第九章：歐洲蛋白質療法市場分析治療藥物市場分析

第十章：亞太地區蛋白質治療藥物市場分析

第十一章：中東與非洲蛋白質治療藥物市場分析

第十二章：南美洲蛋白質治療藥物市場分析

第十三章：公司簡介

拜耳公司
百時美施貴寶公司
第一三共株式會社
雅培公司
賽諾菲公司
賽默飛世爾科技公司
健贊公司
艾伯維公司
Leadiant Biosciences公司
武田藥品工業株式會社
其他主要企業

第十四章附錄

簡介目錄

Product Code: AA11251565

The market is currently experiencing dynamic and robust growth, with its valuation reaching US$ 229.8 billion in 2024. This upward trajectory is expected to continue strongly over the coming years, with projections indicating that the market will nearly double to an estimated valuation of US$ 426.8 billion by 2033. This expansion corresponds to a compound annual growth rate (CAGR) of 7.12% during the forecast period from 2025 to 2033, reflecting sustained and accelerating demand across various therapeutic areas.

Several key factors are driving this impressive growth. One of the primary catalysts is the groundbreaking wave of regulatory approvals in the field of neurology, which has introduced innovative biologic therapies targeting complex neurological conditions. These new treatments are addressing previously unmet medical needs, offering hope for patients with chronic and often debilitating diseases. In parallel, there has been a significant surge in prescriptions for GLP-1 agonists, particularly for metabolic disorders such as diabetes and obesity.

Noteworthy Market Developments

Competitive strategies within the protein therapeutics market are centered around the development of highly targeted therapies such as monoclonal antibodies (mAbs), substantial investments in research and development (R&D), and securing regulatory support to expedite the approval of new biologics. Companies are increasingly focusing on precision medicine approaches that enable treatments tailored to specific disease mechanisms, with monoclonal antibodies exemplifying this trend due to their ability to target molecular pathways.

A notable example of this dynamic occurred in October 2025 when abla Bio entered into a multi-year research collaboration with Takeda aimed at advancing the AI-driven design of protein therapeutics. This partnership illustrates the growing intersection between artificial intelligence and biotechnology, as companies leverage computational tools to accelerate the discovery and optimization of novel protein drugs. As part of the agreement, abla Bio received an upfront payment and ongoing research funding, with the potential to earn success-based payments exceeding $1 billion, underscoring the high stakes and financial commitment involved in cutting-edge protein therapeutics development.

Further highlighting the financial vitality of the sector, in June 2025, Signify Bio, a pioneering biotechnology company focused on harnessing the human body for in situ production of protein therapeutics, announced an oversubscribed $15 million initial financing round. This funding round was led by Actium Group and featured participation from prominent investors such as the Gates Foundation Strategic Investment Fund, Danaher Ventures LLC (a subsidiary of Danaher Corporation), Eli Lilly and Company, and BrightEdge, the venture capital arm of the American Cancer Society (ACS).

Core Growth Drivers

The rapid expansion of cell and gene therapies (CGT) is creating a substantial new demand for highly specialized proteins within the broader protein therapeutics market. These advanced therapies rely heavily on protein-based components, particularly in the form of vectors used to deliver genetic material into patients' cells. By early 2024, there were over 420 gene therapies in clinical trials that utilize protein-based vectors, illustrating the critical role proteins play in the development and function of these innovative treatments.

Emerging Opportunity Trends

The future of the plasma protein therapeutics market is marked by significant growth driven by both an expanding supply chain for raw materials and a rising clinical demand for advanced therapies. A critical factor supporting this growth is the rapid expansion of plasma collection networks, which are essential to meet the increasing therapeutic needs of patients worldwide. In the United States alone, major plasma collectors such as CSL Plasma and Octapharma are scaling their operations significantly. CSL Plasma, for example, has expanded its network to more than 300 collection centers, reflecting the importance of increasing plasma availability to support the production of plasma-derived medicines.

Barriers to Optimization

The high cost associated with the development and manufacturing of protein therapeutics presents a significant barrier that may impede market growth. Developing these advanced biologic drugs involves complex processes, including extensive research, clinical trials, and stringent regulatory requirements, all of which contribute to substantial financial investments. These costs are further amplified during manufacturing, as producing protein-based therapies requires specialized facilities, sophisticated technology, and strict quality control measures to ensure safety and efficacy. The cumulative effect of these expenses often results in high prices for end products, which can limit patient accessibility.

Detailed Market Segmentation

By Product Type, the monoclonal antibodies segment holds a dominant position within the protein therapeutics market, commanding an impressive 51% share that reflects a fundamental shift toward precision medicine. This segment's prominence underscores how monoclonal antibodies have become essential tools for targeting specific disease mechanisms with high accuracy, offering tailored treatments that improve patient outcomes across a range of conditions. Their growing importance is evident in the regulatory landscape, where in 2024, monoclonal antibodies accounted for 13 out of the 16 new biologics approved by the U.S. Food and Drug Administration (FDA).

By Application, the metabolic disorders segment commands an impressive 33% share of the protein therapeutics market, a dominance that directly stems from the global epidemic of diabetes and obesity. These chronic illnesses affect hundreds of millions of people worldwide, creating an urgent need for effective treatments. Protein-based drugs have emerged as vital tools in managing these conditions, offering targeted approaches that help control disease progression and improve patient outcomes. Their growing importance is reflected in the substantial volume of prescriptions written over recent years, underscoring both patient demand and clinical reliance on these therapies.

Segment Breakdown

By Product

Monoclonal Antibodies
Insulin
Fusion Protein
Erythropoietin
Interferon
Human Growth Hormone
Follicle Stimulating Hormone

By Applications

Metabolic Disorders
Immunologic Disorders
Hematological Disorders
Cancer
Hormonal Disorders
Genetic Disorders

By Region

North America
The US
Canada
Mexico
Europe
Western Europe
The UK
Germany
France
Italy
Spain
Rest of Western Europe
Eastern Europe
Poland
Russia
Rest of Eastern Europe
Asia Pacific
China
India
Japan
Australia and New Zealand
South Korea
ASEAN
Rest of Asia Pacific
Middle East and Africa
Saudi Arabia
South Africa
UAE
Rest of MEA
South America
Argentina
Brazil
Rest of South America

Geography Breakdown

North America firmly holds a commanding position in the protein therapeutics market, accounting for over 42% of the global market share. This leadership is rooted in a combination of cutting-edge research capabilities and a well-organized administrative framework that supports innovation and regulatory efficiency. The region's stronghold is further reinforced by advancements in regulatory processes that streamline the development and approval of protein-based therapies.
North America's innovation ecosystem is vibrant and prolific, with an overwhelming number of early-stage developments in protein therapeutics underway. The U.S. Food and Drug Administration's Center for Biologics Evaluation and Research (CBER) oversees thousands of ongoing Investigational New Drug (IND) programs focused on biologics, reflecting the depth and breadth of research activity in the region. This robust pipeline highlights the continuous efforts to discover and develop novel protein-based treatments, addressing a wide range of medical conditions.

Leading Market Participants

Bayer AG
Bristol-Myers Squibb
Daiichi Sankyo Company
Abbott
Sanofi
Thermo Fisher Scientific Inc.
Genzyme Corporation
AbbVie Inc.
Leadiant Biosciences
Takeda Pharmaceutical Company Limited
Other Prominent Players

Table of Content

Chapter 1. Research Framework

1.1 Research Objective
1.2 Product Overview
1.3 Market Segmentation

Chapter 2. Research Methodology

2.1 Qualitative Research
- 2.1.1 Primary & Secondary Sources
2.2 Quantitative Research
- 2.2.1 Primary & Secondary Sources
2.3 Breakdown of Primary Research Respondents, By Region
2.4 Assumption for the Study
2.5 Market Size Estimation
2.6. Data Triangulation

Chapter 3. Executive Summary: Global Protein Therapeutics Market

Chapter 4. Global Protein Therapeutics Market Overview

4.1. Industry Value Chain Analysis
- 4.1.1. Material Provider
- 4.1.2. Manufacturer
- 4.1.3. Distributor
- 4.1.4. Process Type
4.2. Industry Outlook
4.3. PESTLE Analysis
4.4. Porter's Five Forces Analysis
- 4.4.1. Bargaining Power of Suppliers
- 4.4.2. Bargaining Power of Buyers
- 4.4.3. Threat of Substitutes
- 4.4.4. Threat of New Entrants
- 4.4.5. Degree of Competition
4.5. Market Dynamics and Trends
- 4.5.1. Growth Drivers
- 4.5.2. Restraints
- 4.5.3. Challenges
- 4.5.4. Key Trends
4.6. Market Growth and Outlook
- 4.6.1. Market Revenue Estimates and Forecast (US$ Bn), 2020 - 2033
- 4.6.2. Price Trend Analysis
4.7. Competition Dashboard
- 4.7.1. Market Concentration Rate
- 4.7.2. Company Market Share Analysis (Value %), 2024
- 4.7.3. Competitor Mapping & Benchmarking
4.8. Actionable Insights (Analyst Recommendation's)

Chapter 5. Global Protein Therapeutics Market Analysis, By Product

5.1. Key Insights
5.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
- 5.2.1. Monoclonal Antibodies
- 5.2.2. Insulin
- 5.2.3. Fusion Protein
- 5.2.4. Erythropoietin
- 5.2.5. Interferon
- 5.2.6. Human Growth Hormone
- 5.2.7. Follicle Stimulating Hormone

Chapter 6. Global Protein Therapeutics Market Analysis, By Applications

6.1. Key Insights
6.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
- 6.2.1. Metabolic Disorders
- 6.2.2. Immunologic Disorders
- 6.2.3. Hematological Disorders
- 6.2.4. Cancer
- 6.2.5. Hormonal Disorders
- 6.2.6. Genetic Disorders

Chapter 7. Global Protein Therapeutics Market Analysis, By Region

7.1. Key Insights
7.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
- 7.2.1. North America
  - 7.2.1.1. The U.S.
  - 7.2.1.2. Canada
  - 7.2.1.3. Mexico
- 7.2.2. Europe
  - 7.2.2.1. Western Europe
    - 7.2.2.1.1. The UK
    - 7.2.2.1.2. Germany
    - 7.2.2.1.3. France
    - 7.2.2.1.4. Italy
    - 7.2.2.1.5. Spain
    - 7.2.2.1.6. Rest of Western Europe
  - 7.2.2.2. Eastern Europe
    - 7.2.2.2.1. Poland
    - 7.2.2.2.2. Russia
    - 7.2.2.2.3. Rest of Eastern Europe
- 7.2.3. Asia Pacific
  - 7.2.3.1. China
  - 7.2.3.2. India
  - 7.2.3.3. Japan
  - 7.2.3.4. South Korea
  - 7.2.3.5. Australia & New Zealand
  - 7.2.3.6. ASEAN
  - 7.2.3.7. Rest of Asia Pacific
- 7.2.4. Middle East & Africa
  - 7.2.4.1. UAE
  - 7.2.4.2. Saudi Arabia
  - 7.2.4.3. South Africa
  - 7.2.4.4. Rest of MEA
- 7.2.5. South America
  - 7.2.5.1. Argentina
  - 7.2.5.2. Brazil
  - 7.2.5.3. Rest of South America